drugset / Trial / NCT00082212
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
Timeline
- Start
- 2004-11
- Primary completion
- 2007-06
- Completion
- 2007-06
Outcome
Outcome not reported
Stopped: “Due to lack of sufficient efficacy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |